Related Experiment Videos
Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart
Insights
Left ventricular chamber size is crucial for predicting heart failure treatment success. Patients with larger left ventricular end-diastolic dimensions (LVEDD) responded better to hydralazine therapy, showing improved clinical outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic refractory heart failure presents significant treatment challenges.
- Vasodilator therapy is a key treatment modality for heart failure.
Purpose of the Study:
- To investigate the role of left ventricular chamber size in predicting response to vasodilator therapy.
- To determine if left ventricular end-diastolic dimension (LVEDD) influences hydralazine treatment outcomes in heart failure patients.
Main Methods:
- Echocardiography was used to measure LVEDD in 40 patients with chronic heart failure before hydralazine treatment.
- Patients were monitored for clinical improvement and changes in blood urea nitrogen levels during short-term and maintenance hydralazine therapy.
Main Results:
- A significant correlation was observed between LVEDD and changes in stroke volume, filling pressure, and stroke work index.
- Patients with LVEDD ≥ 60 mm showed significant improvement and decreased blood urea nitrogen levels.
- Patients with LVEDD < 60 mm had a higher rate of clinical deterioration and increased blood urea nitrogen levels.
Conclusions:
- Left ventricular chamber size, specifically LVEDD, is a critical determinant of response to hydralazine in severe chronic heart failure.
- Larger LVEDD predicts a favorable response to vasodilator therapy, while smaller LVEDD is associated with poor outcomes.
Abstract:
To examine the importance of left ventricular chamber size in determing the response to vasodilator therapy, we performed echocardiography in 40 patients with chronic refractory heart failure before they were treated with oral hydralazine. The left ventricular end-diastolic dimension (LVEDD) correlated significantly with the per cent change in stroke volume (r = 0.77), left ventricular filling pressure (r = -0.68), and stroke work index (r = 0.87) during short-term drug administration. After 14 to 21 days of maintenance therapy, 15 of 24 patients with an LVEDD greater than or equal to 60 mm were improved, and one was worse; mean blood urea nitrogen decreased from 45.6 to 30.6 mg per deciliter in the 21 patients in this group who completed the study (16.3 to 10.9 mmol per liter) (P less than 0.001). In contrast, only two of 16 patients with an LVEDD less than 60 mm improved, whereas 10 showed clinical deterioration; blood urea nitrogen increased from 49.3 to 64.2 mg per deciliter in the 13 patients in this group who completed the study (17.6 to 22.9 mmol per liter) (P less than 0.01). These findings indicate that left ventricular chamber size is an important factor in the response to hydralazine in patients with severe chronic heart failure.